PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsInsulin glargine
Lantus(insulin glargine)
Abasaglar, Abasria, Basaglar, Lantus, Optisulin, Rezvoglar, Semglee, Soliqua, Suliqua, Toujeo (insulin glargine) is a protein pharmaceutical. Insulin glargine was first approved as Lantus on 2000-04-20. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus and type 2 diabetes mellitus.
Download report
Favorite
Top Prescription Drugs
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Basaglar, Lantus, Rezvoglar, Semglee, Toujeo (discontinued: Basaglar, Lantus, Semglee)
Combinations
Soliqua
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin glargine
Tradename
Proper name
Company
Number
Date
Products
Basaglarinsulin glargineEli LillyN-205692 RX2019-11-15
1 products
Lantusinsulin glargineSanofiN-21081 RX2000-04-20
2 products
Toujeoinsulin glargineSanofiN-206538 RX2015-02-25
2 products
Show 3 discontinued
Insulin glargine
+
Lixisenatide
Tradename
Proper name
Company
Number
Date
Products
Soliqua 100/33insulin glargine and lixisenatideSanofiN-208673 RX2016-11-21
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
basaglarNew Drug Application2019-01-28
basaglar basaglarBiologic Licensing Application2023-11-29
insulin glargineBiologic Licensing Application2025-01-06
insulin glargine insulin glargine solostarBiologic Licensing Application2024-01-03
insulin glargine solostarBiologic Licensing Application2023-11-01
insulin glargine u-300 insulin glargine u-300 maxBiologic Licensing Application2024-09-10
lantusBiologic Licensing Application2023-02-04
lantus lantus solostarBiologic Licensing Application2024-05-23
lantus solostarBiologic Licensing Application2023-07-22
rezvoglarBiologic Licensing Application2024-08-09
Show 6 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
type 1 diabetes mellitusEFO_0001359D003922E10
hyperglycemia—D006943R73.9
Agency Specific
FDA
EMA
Expiration
Code
insulin glargine, Semglee, Biocon Biologics Inc.
11/15/2022Interchangeable excl.
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AE: Insulins and analogues for injection, long-acting
— A10AE04: Insulin glargine
— A10AE54: Insulin glargine and lixisenatide
HCPCS
No data
Clinical
Clinical Trials
713 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E1310456748151
Type 2 diabetes mellitusD003924EFO_0001360E1132437711136
Type 1 diabetes mellitusD003922EFO_0001359E10821711239
HyperglycemiaD006943—R73.91—16—8
HypoglycemiaD007003—E16.2———314
Renal insufficiencyD051437—N19———3—3
FibrosisD005355————11—2
Liver cirrhosisD008103EFO_0001422K74.0———1—1
KetosisD007662—R82.4———1—1
AcidosisD000138EFO_1000014E87.2———1—1
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C95——1——1
Myocardial infarctionD009203EFO_0000612I21——1——1
St elevation myocardial infarctionD000072657————1——1
InfarctionD007238EFO_0009463———1——1
Cystic fibrosisD003550EFO_0000390E84——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic nephropathiesD003928EFO_0000401—————11
Kidney diseasesD007674EFO_0003086N08————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameInsulin glargine
INNinsulin glargine
Description
Insulin glargine recombinant
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB4IYD, 4IYF, 5VIZ
CAS-ID160337-95-1
RxCUI274783
ChEMBL IDCHEMBL1201497
ChEBI ID—
PubChem CID—
DrugBankDB00047
UNII ID2ZM8CX04RZ (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Lantus – Sanofi
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Basaglar – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Toujeo – Sanofi
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Insulin glargine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,714 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
119,534 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use